1 / 21

The Efficacy of Lovastatin in Lowering Cholestrol in African Americans with Primary Hypercholesterolemia

This study explores the effectiveness of Lovastatin in reducing cholesterol levels in African Americans with primary hypercholesterolemia, aiming to prevent coronary issues and reverse atherosclerosis. The experiment focused on LDL and total cholesterol reduction, with minimal side effects observed. Results showed significant lipid reductions, positioning Lovastatin as a beneficial treatment with little side effects for African Americans at risk of heart disease.

Jims
Download Presentation

The Efficacy of Lovastatin in Lowering Cholestrol in African Americans with Primary Hypercholesterolemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Efficacy of Lovastatin in Lowering Cholestrol in African Americans with Primary Hypercholesterolemia Fong,Ronald L. MD; Ward, Harry J. MD Presented by L Aston

  2. Purpose Lovastain is the drug of choice by the NACEP they really favored its use in returning in the reductance of heart disease with very little side effect.

  3. OBJECTIVE This experiment was aim specifically at reducing cholesterol levels by preventing, coronary arrest or reversing coronary aththeroslerosis in African Americans. Thus, lowering Low Density Lipoprotein and total Cholesterol to its maximal level.

  4. Terminologies • 3 –Hydroxyl –3-Methylglutaryl Coenzme A (HMG-CoA ) • Lovastatin (Mevacor) • Low Density Lipoprotein ( LDL) • High density (HDL) • Coronary Heart disease (CHD) • Hypertension (HTN) • Total Cholesterol (TC) • Triglyceride (TG)

  5. CONTINUE • Creatinine Phosphokinase (CPK) • Aspartate Aminotransferase (AST) • Alanine Aminotransferase (ALT) • National Chlestrol Education Program (NCEP)

  6. Exploring Terminology • Low Density Lipoprotein LDL • High Density Lipid HDL • HGM CoA • NCEP

  7. Experiment Process • Specific Criteria • 47 Subjects • Randomization • 10 Weeks • Strict Guide Lines

  8. Frequency • Hemodymic • Dosage of lovastatin • Dietary consultant • Baecke Questionnaire

  9. Mevacor vs Placebo • NO Significant Changes • Relative Dynamics • Side Effects

  10. Blood chemistry • NCEP • Aspartate Aminotransferase (AST) • Creatinine Phosphokinase (CPK) • Alanine Aminotransferase (ALT)

  11. Mevacor success • “Of the 18, 8 had fewer than 2 CHD risk factors and a baseline LDL level of >or= to 190 mg/dL; 3 reached their NCEP II guideline treatment goal <160 mg/dL. The remaining 10 patients without CHD had 2 risk factors and a minimum baseline LDL level of 160 mg/dL; 3 reached the NCEP II target of <130 mg/dL. One out of the 4 patients with CHD reached the NCEP II guideline goal of <100 mg/dL”.

  12. Lipids reduction • Total Cholestrol 14.7% • LDL 20% • HDL 10.5%

  13. Greatest Risk • 47% African American • 27% AA • 40% AA

  14. Conclusion • Lovastatin Inhibits the biosynthesis of HMG-CoA • Thus, reducing LDL and in other studies increase HDL significantly • There are evidence that CHD is reversible with Dietary and strict meds • African Americans Are More At risk for coronary troubles • Mevacor have very little side effect

  15. Refference • Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual • Fong, Ronald L. MD; Ward, Harry J. MD • Maher VM, Thompson GR. HMG-CoA reductase inhibitors as lipid-lowering agents: five years ]

  16. Cont • Tobert JA. Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, Rahway, • Verschuren WM; Jacobs DR; Bloemberg BP; Kromhout D; Menotti A; Aravanis C; Blackburn H; Buzina R; Dontas AS; Fidanza F; et al

More Related